Beste apotheek van Nederland

Harms. In the first trial, the difference in the occurrence of adverse events between the two
treatment groups was not statistically significant. Epigastralgia was reported in 2.5 percent of
testosterone-treated versus 2.2 percent of placebo-treated subjects. In the second trial, the
occurrence of adverse events was not reported.
Efficacy. In the first trial 319 ,men assigned to receive testosterone had median IIEF sexual
intercourse satisfaction scores (range 0–15) of 5 (range 3-10) at 6 months (p <0.01). The
corresponding median score for patients receiving placebo was 4 (range 3–5). The median IIEF–
“EF domain” scores at 6 months of followup for men assigned to receive testosterone and
placebo were 16 (range 6–29) and 8 (range 5–21), respectively. 319 In the second trial, 86 percent
and 93 percent of men in the testosterone and placebo group, respectively, reported that their
erections were “less strong” at 12 weeks of the followup. 316
Oral testosterone versus oral testosterone plus sildenafil. One trial evaluated and
compared the efficacy and harms between oral testosterone alone and oral testosterone combined
with sildenafil. 145 This study enrolled 20 men (mean age: 56 years) with ED of >6 months
duration and symptoms of partial androgen deficiency (mean baseline total testosterone 7.3
nmol/L) who failed to respond to 50-100 mg sildenafil given twice weekly for 2 weeks. These
men were randomized to 2 months of treatment with either oral testosterone undecanoate alone
(120 mg/d) or oral testosterone undecanoate (120 mg/d) plus sildenafil (50-100 mg). Patients
with prostate hypertrophy, prostate cancer, and mammary carcinoma were excluded.
Harms. The study reported that apart from mild headache occurring in three patients taking
sildenafil 100 mg, no serious adverse events were observed. 145
Efficacy. Men in the oral testosterone group reported no significant change in their IIEF–5
scores from 9.9 (SD 1.4) at baseline to 11.1 (1.5) at 2 months (p = 0.27), whereas men in the oral
testosterone plus sildenafil group scored 10.1 (1.3) at baseline and 15.0 (1.4) at 2 month
followup (p < 0.01).
Oral testosterone versus propionyl-L-carnitine plus acetyl-L-carnitine. One trial
evaluated and compared the efficacy and harms for oral testosterone versus propionyl-Lcarnitine
plus acetyl-L-carnitine. 319 In this study, 150 men aged 60-74 years, with symptoms of
androgen decline, and free testosterone below 6 pg/mL, were randomized to receive either 160
mg oral testosterone undecanoate daily for 6 months or 2 gm propionyl-L-carnitine plus 2 gm
acetyl-L-carnitine daily or placebo. 319 Exclusion criteria were prostate enlargement, elevated
PSA, and significant LUTS. Results comparing testosterone and propionyl-L-carnitine plus
acetyl-L-carnitine are reported here.
Harms. The occurrence of adverse events was not statistically significantly different between
the two treatment groups. Epigastralgia was reported in 2.5 percent of the testosterone-treated
versus 0 percent of propionyl-L-carnitine plus acetyl-L-carnitine-treated subjects. Mild headache
was reported for 2.2 percent of the propionyl-L-carnitine plus acetyl-L-carnitine-treated subjects
versus 0 percent for testosterone-treated subjects.
Efficacy. At 6 months, in men assigned to receive testosterone, the median IIEF–”EF
domain” score changed from 8 (range 5-19) at baseline to 16 (range 6-29) (within-group
difference: p <0.01). The corresponding median score in those assigned to the propionyl-Lcarnitine
plus acetyl-L-carnitine group changed from 8 (range 5–22) to 24 (range 8–29) (withingroup
difference: p <0.01).
Oral testosterone plus sildenafil versus sildenafil. One trial evaluated and compared the
efficacy and harms outcomes of oral testosterone plus sildenafil compared with sildenafil
93